Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Rev Esp Enferm Dig ; 113(11): 797-798, 2021 11.
Article in English | MEDLINE | ID: mdl-33845585

ABSTRACT

The benefits of the sedation provided by propofol in digestive endoscopy, either by an endoscopist or an anesthetist, are now undeniable. One of these benefits is a shorter recovery time after endoscopy. Assessment scales are currently available that allow a more efficient discharge from endoscopy units.


Subject(s)
Propofol , Anesthesiologists , Conscious Sedation , Endoscopy, Gastrointestinal , Humans , Hypnotics and Sedatives
2.
Rev Esp Enferm Dig ; 113(10): 736-737, 2021 10.
Article in English | MEDLINE | ID: mdl-33761752

ABSTRACT

The use of telemedicine in penitentiary centers (PCs) is an effective measure to improve quality access to specialized care (secondary prevention) and reduces the inherent costs derived from physical consultations of inmates in hospitals. Regarding the project of our Community Health Service, we enthusiastically began a gastroenterology teleconsultation in our PC at the end of 2020. This modality completes the monthly/on-demand hepatology consultation carried out in this PC since 2015.


Subject(s)
Gastroenterology , Remote Consultation , Telemedicine , Hospitals , Humans , Prisons
3.
Rev Esp Enferm Dig ; 113(9): 685-686, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33393338

ABSTRACT

Recently, we´ve noticed an increasing in the whole propofol dose in endoscopy in relation to cannabis use. This issue is not described in the current data (technical datasheet). We´re really concern that, unfortunately, it´ll be more and more frequent.


Subject(s)
Anesthesia , Cannabis , Propofol , Conscious Sedation , Endoscopy , Endoscopy, Gastrointestinal , Humans , Hypnotics and Sedatives
6.
Rev Esp Enferm Dig ; 110(7): 472-473, 2018 07.
Article in English | MEDLINE | ID: mdl-29900749

ABSTRACT

Two cases of a chemical dissolution of gastric phytobezoars are presented. The novel approach of that management is the pharmacological mixture than completely made disappear the bezoars in patients fated to surgery removal.


Subject(s)
Bezoars/drug therapy , Carbonated Beverages , Cellulase/therapeutic use , Gastrointestinal Agents/therapeutic use , Pancreatin/therapeutic use , Stomach Diseases/drug therapy , Ursodeoxycholic Acid/therapeutic use , Drug Therapy, Combination , Humans , Treatment Outcome
11.
Rev Esp Enferm Dig ; 109(7): 537, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28593788

ABSTRACT

We present a case of a young 16 year old patient that had an esophageal perforation in the context of eosinophilic esophagitis. The esophagus showed vertical lacerations and mucosal thickness on endoscopy, thus a biopsy was performed in the proximal section which resulted in profuse bleeding due to a deep mucosal tear. A subsequent computed tomography scan revealed a perforation. Due to the absence of symptoms the patient was managed conservatively. The patient was discharged within 48 hours after admission. The histopathology analysis showed a massive eosinophilic infiltration of the mucosa that verified the clinical suspicion.


Subject(s)
Biopsy/adverse effects , Eosinophilic Esophagitis/complications , Eosinophilic Esophagitis/diagnosis , Adolescent , Eosinophilic Esophagitis/diagnostic imaging , Esophagus/pathology , Gastrointestinal Hemorrhage/etiology , Humans , Male
20.
Gastroenterol. hepatol. (Ed. impr.) ; 37(10): 551-557, dic. 2014. tab
Article in Spanish | IBECS | ID: ibc-129645

ABSTRACT

INTRODUCCIÓN: Existe escasa información sobre la precisión diagnóstica oncológica de la elevación del antígeno carcinoembrionario (CEA) más de tres veces por encima del valor normal. OBJETIVOS: Determinar la prevalencia de procesos oncológicos del rango establecido del CEA y el coste medio que supone el estudio. MÉTODOS: Estudio retrospectivo de todos los pacientes derivados a consultas externas de Aparato Digestivo o Medicina Interna para estudio de patología tumoral en relación con un CEA entre 3 y 10 ng/ml desde 2.001 a 2.007. RESULTADOS: Cien pacientes (60 hombres y 40 mujeres), 67,4 ± 14,2 años, y con nivel basal de 5,8 ± 1,7 ng/ml. Los síntomas/signos guía más relevantes fueron alteraciones analíticas (19, 19%). Se diagnosticaron 4 cánceres (uno gástrico, 2 de pulmón y uno de colon). En cuanto a la patología no oncológica, en 49 pacientes (49%) no se detectó ningún proceso relacionado, y en 47 (47%) se confirmaron otros diagnósticos asociados a aumento de dicho marcador. En el seguimiento (54,3 ± 24,6 meses) se detectó un cáncer laríngeo, una leucemia aguda mieloide y un cáncer de colon. El CEA basal de los pacientes con cáncer no tuvo diferencias con respecto a aquellos sin patología oncológica (6,6 ± 2,4 vs. 5,8 ± 1,7 ng/ml; p = 0,2). El gasto medio por paciente fue de 503,6 ± 257,6 euros. CONCLUSIONES: Existe una baja proporción (7%) de pacientes con proceso oncológico en relación con la elevación leve del CEA. Existe un gasto económico no desdeñable asociado directa e indirectamente al estudio de estos pacientes


INTRODUCTION: There is little information on the oncologic diagnostic accuracy of carcinoembryonic antigen (CEA) levels more than 3-fold above normal. OBJECTIVES: To determine the prevalence of underlying cancer in patients with mild CEA elevation and the mean cost per patient of CEA determination. Methods A retrospective study was carried out in all patients with CEA elevation (3-10 ng/ml) and suspicion of cancer referred to the gastroenterology or internal medicine outpatient units from 2001 to 2007. RESULTS: We studied 100 patients (60 men and 40 women), with a mean age of 67.4 ± 14.2 years and baseline CEA of 5.8 ± 1.7 ng/ml. The most important symptoms and signs were laboratory abnormalities (19 patients [19%]). Cancer was diagnosed in 4 patients (one gastric, 2 lung and one colon). Among patients without malignancies, 49 patients (49%) had no related processes, and 47 (47%) had benign diseases. During follow-up, one laryngeal cancer, one acute myeloid leukemia, and one colon cancer were detected (54.3 ± 24.6 months). We found no differences between baseline CEA levels in patients with and without cancer (6.6 ± 2.4 vs. 5.8 ± 1.7 ng/ml, p = 0.2). The mean cost per patient was 503.6 ± 257.6 euros. CONCLUSIONS: Cancer was detected in a small proportion (7%) of patients with mild CEA elevation. The study of these patients is directly and indirectly associated with a not inconsiderable cost


Subject(s)
Humans , Carcinoembryonic Antigen/analysis , Early Detection of Cancer/methods , Retrospective Studies , Biomarkers, Tumor/analysis , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...